Frankfurt
02.10.26 | 08:01
3,020 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDEXUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 25.09. | Medexus Pharmaceuticals Inc: Medexus Pharmaceuticals holders approve AGM resolutions | 1 | Stockwatch | ||
| 24.09. | Medexus Pharmaceuticals Inc.: Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors | 633 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders... ► Artikel lesen | |
| 11.08. | Medexus Pharmaceuticals Inc. Q1 Sales Increase | 4 | RTTNews | ||
| 10.08. | Medexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date | 818 | Newsfile | Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investmentsCommercial... ► Artikel lesen | |
| 30.07. | Medexus Pharmaceuticals Inc.: Medexus Schedules First Fiscal Quarter 2027 Conference Call | 486 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August... ► Artikel lesen | |
| 26.06. | Medexus Pharmaceuticals reports Q4 results | 15 | Seeking Alpha | ||
| 26.06. | Medexus Pharmaceuticals Inc.: Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection | 804 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business... ► Artikel lesen | |
| 16.06. | Medexus Pharmaceuticals Inc.: Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call | 583 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June... ► Artikel lesen | |
| 09.06. | Medexus Pharmaceuticals Inc.: Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada | 687 | Newsfile | UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro (dorocubicel)Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medexus's... ► Artikel lesen | |
| 15.04. | Medexus Pharmaceuticals Inc.: Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation | 800 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization... ► Artikel lesen | |
| 11.02. | Medexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection | 639 | Newsfile |
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided... ► Artikel lesen | |
| 03.02. | Medexus Pharmaceuticals Inc.: Medexus Schedules Third Fiscal Quarter 2026 Conference Call | 433 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday... ► Artikel lesen | |
| 20.11.25 | Medexus Pharmaceuticals Inc.: Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares | 455 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted... ► Artikel lesen | |
| 17.11.25 | Medexus Pharmaceuticals Inc.: Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares | 380 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National... ► Artikel lesen | |
| 13.11.25 | Medexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection | 641 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business... ► Artikel lesen | |
| 04.11.25 | Medexus Pharmaceuticals Inc.: Medexus Schedules Second Fiscal Quarter 2026 Conference Call | 564 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday,... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| NOVARTIS | 124,98 | -0,14 % | CH-Verlauf: Fester dank Novartis und Nestlé, Roche fallen ab | Zürich - Der Schweizer Aktienmarkt ist mit Schwung in die neue Woche gestartet und hat die Marke bei 14'000 klar zurückerobert. In der Folge konnte er indes dieses Niveau nicht ganz halten. Gestützt... ► Artikel lesen | |
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead | ||
| AURORA CANNABIS | 3,518 | +0,86 % | Aurora Cannabis: Beschwerde bringt den Deal ins Wanken | ||
| GSK | 20,870 | -1,04 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2500 Pence auf "Buy" belassen. B7H3-Antikörper seien eine der am meisten unterschätzten Chancen... ► Artikel lesen | |
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| MERCK & CO | 128,18 | 0,00 % | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 448,45 | +0,04 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| ABBOTT LABORATORIES | 86,72 | +0,14 % | Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday |
Das Unternehmen MEDEXUS PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDEXUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.